Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.

Journal of applied genetics - 1 Sept 2023

Kanduła Zuzanna, Janowski Michał, Więckowska Barbara, Paczkowska Edyta, Mroczkowska-Bękarciak Aleksandra, Sobas Marta, Lewandowski Krzysztof

Abstract excerpt

Apart from the driver mutations, high molecular risk (HMR) variants and other factors have been reported to influence the prognosis of primary myelofibrosis (PMF). The aim of our study was to investigate the impact of laboratory and molecular characteristics at the time of diagnosis (TOD) on the PMF outcome. The study group consisted of 82 patients recruited from three Polish university centers. Among the driver...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Janus Kinase 2
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Prognosis

Share to Thrombocytopenia

Source

Open in PubMed Open full text

Identifiers

PMID: 37507589
DOI: 10.1007/s13353-023-00771-x
PMCID: PMC10457229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis.PMID 37507589Read ↗

Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease.Semantic proximity Read ↗

The new WHO classification for essential thrombocythemia calls for revision of available evidences.Semantic proximity Read ↗

Clonal Megakaryocyte Dysplasia with Isolated Thrombocytosis Is a Distinct Myeloproliferative Neoplasm Phenotype.Semantic proximity Read ↗

Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progressionSemantic proximity Read ↗

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis.Semantic proximity Read ↗

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.Semantic proximity Read ↗

Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.Semantic proximity Read ↗

Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates.Semantic proximity Read ↗

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.Semantic proximity Read ↗

Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.Semantic proximity Read ↗

Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms.Semantic proximity Read ↗

Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.